Conclusions

In subjects with chronic fibrosing ILDs and a progressive phenotype who received placebo in the INBUILD trial, the annual rate of decline in FVC was numerically greater in subjects with a UIP-like fibrotic pattern on HRCT than in those with other fibrotic patterns on HRCT.
The relative treatment effect of nintedanib on slowing the rate of FVC decline was consistent between subjects with a UIP-like fibrotic pattern and other fibrotic patterns on HRCT and similar to that observed in subjects with IPF in the INPULSIS trials.⁴
Nintedanib was associated with a numerically reduced risk of an absolute decline in FVC ≥10% predicted or death in both subgroups by fibrotic pattern on HRCT.